Abstract:It has been previously reported that vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 are important for the occurrence and development of non-small cell lung cancer (NSCLC). The present study was designed to detect the serum levels of VEGF and MMP-9 in NSCLC, and to explore their diagnostic and prognostic values. A total of 543 cases were involved, of which 332 were NSCLC (272 cases in the pretreatment group and 60 cases in the postoperative group), 91 were patients with benign lung diseases and 120 were healthy controls. The serum levels of VEGF and MMP-9 were determined by Luminex multiplex technology. The serum levels of VEGF and MMP-9 were found to be significantly higher in the pretreatment group than those in the patients with benign lung diseases and healthy controls (VEGF, P<0.0001; MMP-9, P<0.0001). Compared with the pretreatment group, the serum levels of VEGF and MMP-9 in the postoperative group were significantly decreased (VEGF, P=0.005; MMP-9, P=0.002), and the levels of VEGF and MMP-9 in the pretreatment group of patients with stages III and IV were higher than those with stages I and II (VEGF, P<0.0001; MMP-9, P=0.021). In addition, the levels of VEGF and MMP-9 were found to closely correlate with lymph node metastasis (VEGF, P<0.0001; MMP-9, P<0.0001) in the pretreatment group, while being independent of other clinicopathological parameters (P>0.05). Furthermore, a positive correlation was observed between the serum levels of VEGF and MMP-9 (r=0.159; P=0.009). A receiver operating characteristic curve analysis showed that the diagnostic value of MMP-9 was higher than that of VEGF in the pretreatment group. The log-rank test indicated that the inoperable NSCLC patients with low levels of VEGF exhibited a significantly longer overall survival time than those with high VEGF levels (P<0.0001). Additionally, the serum levels of VEGF and lymph node metastasis were identified as independent prognostic factors of the inoperable NSCLC patients in a multivariate Cox regression analysis (P<0.05). These results indicated that VEGF and MMP-9 may be potential biomarkers for the diagnosis and prognosis of NSCLC.

Percutaneous Microwave Ablation (mwa) Increased the Serum Levels of Vegf and Mmp-9 in Stage I Non-Small Cell Lung Cancer (Nsclc)

Microwave ablation enhances the systemic immune response in patients with lung cancer

Efficacy and Safety of Microwave Ablation in the Treatment of Patients with Oligometastatic Non-Small-cell Lung Cancer: a Retrospective Study.

Safety and Effectiveness Analysis of Percutaneous Microwave Thermal Ablation Therapy Combined Brachytherapy for Lung Malignant Lesion

Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC

Combined microwave ablation and antiangiogenic therapy to increase local efficacy

Percutaneous Microwave Ablation of Stage I Medically Inoperable Non‐small Cell Lung Cancer: Clinical Evaluation of 47 Cases

Immunogenic change after percutaneous microwave ablation in pulmonary malignancies: Variation in immune cell subsets and cytokines in peripheral blood

Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results

A Study of Microwave Ablation for Small Cell Lung Cancer.

Plasma Level and Prognostic Significance of VEGF,bFGF and MMP-9 in Patients with Advanced Non-Small-cell Lung Cancer

Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Programmed Death-Ligand 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes in Advanced Non-Small Cell Lung Cancer Treated with Microwave Ablation and Chemotherapy.

CT‐guided Microwave Ablation in Patients with Lung Metastases from Breast Cancer

Multicentre Study of Microwave Ablation for Pulmonary Oligorecurrence after Radical Resection of Non-Small-cell Lung Cancer.

Microwave Ablation Combined with EGFR-TKIs Versus Only EGFR-TKIs in Advanced NSCLC Patients with EGFR-sensitive Mutations

Microwave Ablation Followed by Immediate Biopsy in the Treatment of Non-Small Cell Lung Cancer

Microwave Ablation for the Treatment of Peripheral Ground-Glass Nodule-Like Lung Cancer: Long-term Results from a Multi-Center Study.

Clinical study of microwave ablation combined with radiochemotherapy in the treatment of Stage Ⅲ peripheral non-small cell lung cancer

Microwave Ablation As Local Consolidative Therapy for Patients with Extracranial Oligometastatic EGFR-mutant Non-Small Cell Lung Cancer Without Progression after First-Line EGFR-TKIs Treatment

Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology